How to Help Your Patients Find Cyclopentolate in Stock: A Provider's Guide

Your Patients Need Cyclopentolate — Here's How to Help Them Find It

As an eye care provider, you know how essential Cyclopentolate is to your practice. It's the workhorse cycloplegic for pediatric refraction, a reliable mydriatic for comprehensive exams, and a drug your patients depend on you to have in stock. But with the shortage now in its sixth year, many practices are facing recurring supply gaps that directly impact patient care.

This guide offers practical, actionable strategies to help your patients access Cyclopentolate — or appropriate alternatives — despite the ongoing supply constraints.

Current Availability Landscape

As of early 2026, Cyclopentolate supply comes from three manufacturers:

• Alcon — Cyclogyl (brand) in 0.5%, 1%, and 2% concentrations
• Sandoz — Generic Cyclopentolate HCl, primarily 1%
• Bausch Health — Generic Cyclopentolate HCl, 1%

The FDA continues to list Cyclopentolate as in shortage. Akorn's 2023 closure remains the primary driver of the supply gap, and no new manufacturers have entered the market. Supply is intermittent — practices in some regions report adequate stock while others face persistent shortages.

For the full shortage timeline and clinical context, see: Cyclopentolate Shortage: What Providers and Prescribers Need to Know in 2026.

Why Patients Can't Find Cyclopentolate

Understanding the patient's perspective helps you anticipate and address their challenges:

• Pharmacy stock-outs: Most retail pharmacies carry limited ophthalmic inventory. During a shortage, Cyclopentolate is one of the first products to sell out.
• Limited awareness: Patients may not know to call ahead, check multiple pharmacies, or explore specialty options.
• Concentration confusion: A prescription for 1% may not be fillable if only 0.5% or 2% is in stock, and patients don't know they can ask about alternatives.
• Cost concerns: When generic is unavailable, patients may be quoted the brand-name Cyclogyl price ($100-$200+) and decline to fill.
• In-office vs. take-home: Some patients may need a take-home prescription for conditions like uveitis, and the shortage affects both channels.

What Providers Can Do: 5 Actionable Steps

Step 1: Maintain Multiple Supplier Relationships

Don't rely on a single distributor for your in-office Cyclopentolate supply. Build relationships with:

• Your primary pharmaceutical distributor (McKesson, Cardinal Health, AmerisourceBergen)
• Specialty ophthalmic distributors (e.g., Amcon Labs, Dry Eye Rescue wholesale)
• Direct accounts with manufacturers (particularly Alcon for Cyclogyl)
• Local compounding pharmacies as a backup source

When one channel runs dry, having alternatives already established saves time and prevents care delays.

Step 2: Direct Patients to Medfinder for Providers

Medfinder tracks real-time medication availability across pharmacies. You can use it to:

• Identify pharmacies near your practice with Cyclopentolate in stock
• Provide patients with specific pharmacy recommendations rather than sending them on a blind search
• Monitor availability trends to anticipate supply changes

Consider adding Medfinder to your front desk workflow — staff can check availability before patients leave the office with a prescription.

Step 3: Write Flexible Prescriptions

When clinically appropriate, provide flexibility that increases the chance of a successful fill:

• Include "or equivalent concentration" in notes when switching between 0.5%, 1%, or 2% is acceptable
• Consider writing a backup prescription for an alternative agent (e.g., Tropicamide or Atropine) in case Cyclopentolate can't be found
• If a compounding pharmacy is an option, write a separate prescription specifying the compounded preparation

Step 4: Educate Your Staff and Patients

Proactive communication reduces frustration on all sides:

• Train front desk staff to inform patients about the shortage when scheduling appointments
• Create a patient handout explaining the shortage and listing local pharmacy resources
• Post information in your waiting room and on your practice website
• Share patient-friendly resources like: How to Find Cyclopentolate in Stock Near You

Step 5: Establish Clear Clinical Protocols for Alternatives

Having documented protocols for when to use alternatives helps maintain consistency across your practice:

• Tropicamide 1%: Acceptable for routine dilated fundus exams and may be adequate for cycloplegic refraction in older children and adults. Consider for patients where full cycloplegia isn't critical.
• Atropine 1%: Reserve for situations requiring maximum cycloplegia — young children under 5, heavily pigmented irides, suspected accommodative esotropia. Counsel patients about the 7-14 day duration.
• Homatropine 2% or 5%: Consider as an intermediate option when available. Duration of 1-3 days is a reasonable compromise.
• Phenylephrine 2.5% or 10%: For mydriasis only (no cycloplegia). Often used in combination with other agents.

For detailed comparison of alternatives, direct patients to: Alternatives to Cyclopentolate.

Alternative Agents: Quick Reference

Here's a concise clinical comparison for your practice:

• Cyclopentolate 1%: Onset 30-45 min | Duration 24-48 hr | Cycloplegia: Strong | Gold standard for pediatric refraction
• Tropicamide 1%: Onset 20-40 min | Duration 4-8 hr | Cycloplegia: Moderate | Good for routine dilation; emerging evidence for cycloplegic refraction
• Atropine 1%: Onset 30-40 min | Duration 7-14 days | Cycloplegia: Maximum | Best for young children with dark irides; long recovery
• Homatropine 5%: Onset 40-60 min | Duration 1-3 days | Cycloplegia: Moderate | Intermediate option; less commonly stocked
• Phenylephrine 2.5%: Onset 15-30 min | Duration 3-6 hr | Cycloplegia: None | Mydriasis only; often used in combination

Workflow Tips for Managing the Shortage

Based on what practices have found effective during this extended shortage:

• Track usage: Monitor your Cyclopentolate consumption weekly and set reorder triggers at 2-3 weeks of supply remaining.
• Conserve strategically: Reserve Cyclopentolate for cases where it's most needed (pediatric cycloplegic refraction) and use Tropicamide for routine adult dilated exams.
• Batch pediatric exams: If supply is very limited, consider scheduling pediatric cycloplegic refractions on specific days to optimize use of available stock.
• Check expiration dates: During shortages, it's tempting to overstock. Ensure your inventory management prevents waste from expired product.
• Document everything: If you use an alternative agent due to the shortage, document the clinical rationale in the patient's chart.

Final Thoughts

The Cyclopentolate shortage requires providers to be both clinically adaptable and operationally proactive. By diversifying your supply chain, leveraging tools like Medfinder for Providers, educating your team and patients, and maintaining clear protocols for alternative agents, you can continue to deliver excellent eye care despite the constraints.

For patients who are concerned about cost, point them to: How to Save Money on Cyclopentolate in 2026. And for providers looking to help patients save, see: How to Help Patients Save Money on Cyclopentolate.